Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

Phase 2 Study to Explore the Efficacy of Novel Proteasome Inhibitor in

Patients with Relapsed and Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, Calif. and NORWALK, Conn., Aug. 15 /PRNewswire/ -- The Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today announced the enrollment of the first patient in a multi-center Phase 2 clinical trial to study Proteolix's potent and selective proteasome inhibitor, carfilzomib (PR-171), in patients with relapsed and refractory multiple myeloma. Ten MMRC Member Institutions will participate in the study, under the MMRC leadership of Melissa Alsina, MD, H. Lee Moffitt Cancer Center & Research Institute. The nine additional sites are the City of Hope, Emory University, Cancer Center at Hackensack University Medical Center, Mayo Clinic, Princess Margaret/University Health Network, Saint Vincent's Comprehensive Cancer Center, University of Michigan, and Washington University.

The MMRC is the only research model of its kind that brings together 13 leading academic institutions to accelerate the development of novel and combination treatments for multiple myeloma, an incurable cancer of the plasma cell.

"Proteasome inhibitors are an important class of drugs for the treatment of multiple myeloma and we are proud to work with Proteolix to advance the clinical development of carfilzomib," said Kathy Giusti, Founder and Chief Executive Officer of the MMRC. "This trial and the others the MMRC are facilitating underscore our commitment to bring better, more effective treatments to myeloma patients as quickly as possible."

The trial will evaluate the overall response rate (ORR) for two cycles of carfilzomib in patients with multiple myeloma who have previously received specific FDA-approved therapies, have relapsed after two or more of such therapies, and are refractory to the most recently received therapy. Secondary objectives of this study include safety and tolerability, clinica
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... MARLTON, N.J. , March 4, 2015 ... brand protection and serialization solutions, announced it will be ... Roosevelt Paper. The live event, "How to Boost Manufacturing ... on Wednesday, March 18th at 2:00 PM EDT.  ... Officer for Acsis, and John Gordon , Chief ...
(Date:3/4/2015)... 4, 2015 UPM Pharmaceuticals, a division of ... Sprout Pharmaceuticals to manufacture Flibanserin 100 mg tablets. Sprout ... the first drug approved to treat hypoactive sexual desire ... dysfunction. The tablets will be manufactured at ... Tennessee . Dr. John M. ...
(Date:3/4/2015)... -- Results of the recent study, Results From a ... Positive Margin Detection , were presented as part of ... Annual Miami Breast Cancer Conference last week. ... MD, FACS, Professor of Surgery at the Sackler School ... of MarginProbe,s efficiency and accuracy when used consecutively to ...
Breaking Medicine Technology:UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 2UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 3New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2
... Valley Technologies, Inc. (LVT) is pleased to announce ... the U.S. Food and Drug Administration (FDA).  On ... with no Form 483 observations and no discussion ... relating to cGMP (current Good Manufacturing Practices).  Additionally, ...
... MORRISVILLE, N.C., Jan. 9, 2012  nContact, Inc., the ... its technology will be presented by physicians in ... Atrial Fibrillation Symposium, January 12-14 in Boston, Massachusetts. ... with VisiTrax® and next generation EPi-Sense™ Coagulation System ...
Cached Medicine Technology:nContact's Cardiac Ablation Technology to be Presented in Two Noteworthy Posters at Boston Atrial Fibrillation Symposium 2012 2
(Date:3/4/2015)... (PRWEB) March 04, 2015 With the growing ... the lives of our teens and young adults, combined with ... difficult and confusing to try to keep up with what ... fad or trend is replaced on a daily basis. , ... substances, and the slang that is used to discreetly talk ...
(Date:3/4/2015)... 2015 Alliance Healthcare Foundation (AHF), a ... those in need in San Diego and Imperial Counties, ... its Mission Support Grants program with awards totaling $1 ... for AHF’s Mission Support Grants program. Grant recipients were ... trustees and program committee, as well as the community ...
(Date:3/4/2015)... 04, 2015 The Global Liquefied ... in 2014 and is estimated to grow to ... 4.0% from 2014 to 2019. , Browse through ... for an analysis of industry trends, segments & ... liquefied petroleum gas market is classified into source, ...
(Date:3/4/2015)... RapidScale, a global cloud services innovator, is attending ... 16th-18th. They are hosting Booth #1010 on the expo ... engineering executives in attendance to provide demos and discuss ... include William Hiatt, CTO; Jeff Richards, Cloud Delivery Manager; ... Support Manager. , RapidScale is also hosting two ...
(Date:3/4/2015)... According to a new report published ... the U.S. suffer from gastroesophageal reflux disease (GERD), more ... to control acid production, but these can have side ... the problem and lead to other uncomfortable digestive conditions. ... the lower esophageal sphincter does not function properly. Anti-reflux ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:Alliance Healthcare Foundation Awards $1 million through Mission Support Grants Program 2Health News:Alliance Healthcare Foundation Awards $1 million through Mission Support Grants Program 3Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 2Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 3Health News:Rapidscale to Host First Cloudtalk Events at Channel Partners in Las Vegas 2Health News:Rapidscale to Host First Cloudtalk Events at Channel Partners in Las Vegas 3Health News:New and Proven Acid Reflux Treatments Offer Relief to Millions of Americans 2Health News:New and Proven Acid Reflux Treatments Offer Relief to Millions of Americans 3
... been substantially ramped up in Canadian hospitals since the ... infections post-SARS have multiplied even faster, a new Queen,s ... Dick Zoutman, the national survey is a six-year follow-up ... to the outbreak of SARS (Severe Acute Respiratory Syndrome). ...
... SGP ) will webcast its "R&D Update" ... Monday, Nov. 24, 2008. Fred Hassan,Schering-Plough,s chairman and ... Schering-Plough Research Institute, and other,members of management will ... is to provide an update on the company,s ...
... increase risk 8-fold, researchers say , , FRIDAY, Nov. 7 ... is not healthy for you, but now a new ... among obese smokers. , "We know that obesity and ... lead researcher Annemarie Koster, an epidemiologist at the U.S. ...
... Nov. 7 Triple-S,Management Corporation (NYSE: GTS ... Chief Executive Officer, and Juan-Jose Roman,Finance Vice President ... at the Credit Suisse 2008 Healthcare Conference in ... time. The presentation will be,broadcast live through the ...
... cholesterol tests that identify the risk of heart disease ... Add the responsibility of providing sustained care for ... important. , Yet, grandmothers in the first two years ... to protect their health compared to grandmothers the same ...
... disease of biblical times, leprosy, also known as Hansen,s ... "Approximately 150 cases are diagnosed each year with ... leprosy, says James Krahenbuhl, Ph.D., director of the Health ... Baton Rouge, LA. "We believe there are more cases ...
Cached Medicine News:Health News:'Superbugs' on the rise in Canadian hospitals, new Queen's study shows 2Health News:Smoking Coupled With Obesity Raises Death Risk 2Health News:Smoking Coupled With Obesity Raises Death Risk 3Health News:Triple-S Management Corporation to Present at Credit Suisse 2008 Healthcare Conference 2Health News:The health burden of raising a grandchild 2Health News:The health burden of raising a grandchild 3Health News:Forgotten, but not gone: Leprosy still present in the US 2
... system represents a breakthrough for patients experiencing ... The system gathers bone during decompression, bone ... bone into the implant's chamber produces a ... from the iliac crest. The BAK/C implant ...
Intera 3.0T is the most compact high-field clinical whole-body MR system in the world, bringing 3.0T capabilities "out of the tunnel" and into the light of an open, patient-friendly design....
... Intradiscal Instruments are designed to provide ... aid in disc removal, endplate preparation, ... set consists of several Vertebral Spreaders, ... and a Vertebral Body Positioner. Used ...
... Platelet Concentrate System is a point-of-care system ... Concentrate (also referred to as Platelet Rich ... (PPP) from a small sample of blood. ... natural growth factors, which are found in ...
Medicine Products: